Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX:CYP) has announced positive safety and efficacy data from a 28 day analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001.

Australia may have avoided making a detailed commitment on extending the data protection period for biologics in the Trans-Pacific Partnership Agreement but the issue will almost certainly be part of negotiations for a new free trade agreement with the European Union.

Australian cancer company Sirtex (ASX:SRX) has announced it has accepted a $1.9 billion takeover bid from Chinese company CDH Genetech Limited.

Springboard Enterprises Australia’s latest program round – Empower, Evolve, Escalate or E3 - is now open for applications. The program is designed to help develop the next generation of early-stage, female startup founders or leaders from a broad range of activities, including the life sciences and engineering.

Regenerative medicine company Orthocell (ASX:OCC) has announced the presentation of updated positive results from a study of its tendon cell therapy treatment for tennis elbow in 24 patients who suffered work-related injuries and disability.

Sydney headquartered clinical research organisation Novotech has signed a Memorandum of Understanding (MOU) with the China Medical University Hospital (CMUH) in Taiwan.

New leadership for MSD Australia and New Zealand with the departure of Riad El-Dada for another position in the company's global organisation.